Exscientia nets $225 million in latest funding round

Exscentia

Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.

Read More

New Victorian AI program launches with $100 M VC fund

Face on Blueprint

An accelerator program targeting mature artificial intelligence (AI) companies has been launched in Victoria, aiming to be supported by a $100 million venture capital fund. The Boab AI Scaleup program has already received about $1.5 million backing from LaunchVic and $8 million in private sector capital last year via venture capital manager, Artesian.

Read More